Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis

Abstract: Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported. Conclusion Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.

Object Details

• Alternative title: Segurança na mudança direta de natalizumabe para fingolimode em um grupo de pacientes com esclerose múltipla e positivos para JCV
• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis ; volume:74 ; number:08 ; year:2016 ; pages:650-652 ; Arquivos de neuro-psiquiatria ; 74, Heft 08 (2016), 650-652

Contributors, Places and Time

• Contributor: Fragoso, Yara Dadalti ; Alves-Leon, Soniza Vieira ; Becker, Jefferson ; Brooks, Joseph Bruno Bidin ; Correa, Eber Castro ; Damasceno, Alfredo ; Gama, Paulo Diniz da ; Gama, Rodrigo Assad da ; Matta, Andre Palma da Cunha ; Maciel, Ernane Pires ; Cristina d’Avila Winckler, Thereza

Further information

• DOI: 10.1590/0004-282X20160090
• URN: urn:nbn:de:101:1-2023101912332969449654
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 14.08.2025, 10:48 AM CEST